Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study

被引：3
|
作者：
Groen, Kaz
Stege, Claudia A. M.
Nasserinejad, Kazem
de Heer, Koen
Van Kampen, Roel J. W.
Leijs, Maria B. L.
Thielen, Noortje
Westerman, Matthijs
Wu, Ka Lung
Ludwig, Inge
Issa, Djamila
Velders, Gerjo A.
Vekemans, Marie-Christiane
van de Donk, Niels W. C. J.
Timmers, Gert-Jan
Sonneveld, Pieter
Seefat, Maarten R.
Croon-de Boer, Fransien
Tick, Lidwine W.
van der Spek, Ellen
De Waal, Esther G. M.
Sohne, Maaike
Ypma, Paula F.
Nijhof, Inger S.
Klein, Saskia K.
Levin, Mark-David
Zweegman, Sonja
机构：
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-152112
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
80
引用
收藏
页数：5
相关论文
共 50 条
  • [11] A Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone ( DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) Study
    Nooka, Ajay K.
    Joseph, Nisha S.
    Gupta, Vikas A.
    Hofmeister, Craig C.
    Dhodapkar, Madhav V.
    Burton, Bryan J.
    Ahmed, Hafsa M.
    Linton, Darrian
    Cortoos, Annelore
    Lin, Thomas S.
    Labotka, Richard
    Noga, Stephen J.
    Kaufman, Jonathan L.
    Lonial, Sagar
    BLOOD, 2023, 142
  • [12] Preliminary Results of Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Newly Diagnosed Multiple Myeloma (NDMM) Transplant Eligible (TE) Patients
    Crusoe, Edvan De Queiroz
    Salvino, Marco Aurelio
    Silva, Sarah Queiroz
    Santos, Herbert Henrique de Melo
    Santos, Allan de Souza
    Almeida, Alessandro de M.
    Vieira, Lucas de Oliveira
    Fonseca, Cleverson Alves
    Lucas, Larissa Ferreira
    Leal, Joanna
    Santos, Mariane Melo
    Santos, Juliana Andrade
    Adorno, Elisangela
    Hungria, Vania T. M.
    Arruda, Maria da Gloria B.
    BLOOD, 2020, 136
  • [13] Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized Unito-EMN10 Study
    Larocca, Alessandra
    Corradini, Paolo
    Mina, Roberto
    Cascavilla, Nicola
    Liberati, Anna Marina
    Pescosta, Norbert
    Petrucci, Maria Teresa
    Ciccone, Giovannino
    Capra, Andrea
    Patriarca, Francesca
    Scalabrini, Delia Rota
    Innao, Vanessa
    Poggiu, Marco
    Cea, Michele
    Zambello, Renato
    Baraldi, Anna
    Belotti, Angelo
    Cellini, Claudia
    Galli, Monica
    Grasso, Mariella
    Aquino, Sara
    Casaluci, Gloria Margiotta
    De Sabbata, Giovanni
    Ballanti, Stelvio
    Offidani, Massimo
    Mancuso, Katia
    Boccadoro, Mario
    Bringhen, Sara
    BLOOD, 2019, 134
  • [14] Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial
    Zweegman, Sonja
    Stege, Claudia A. M.
    Haukas, Einar
    Schjesvold, Fredrik H.
    Levin, Mark-David
    Waage, Anders
    Leys, Rineke B. L.
    Klein, Saskia K.
    Szatkowski, Damian
    Axelsson, Per
    Trung Hieu Do
    Knut-Bojanowska, Dorota
    van der Spek, Ellen
    Svirskaite, Asta
    Klostergaard, Anja
    Salomo, Morten
    Blimark, Celine
    Ypma, Paula F.
    Mellqvist, Ulf-Hendrik
    Poddighe, Pino J.
    Stevens-Kroef, Marian
    van de Donk, Niels W. C. J.
    Sonneveld, Pieter
    Hansson, Markus
    van der Holt, Bronno
    Abildgaard, Niels
    HAEMATOLOGICA, 2020, 105 (12) : 2879 - 2882
  • [15] Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone: a quadruplet intensified treatment for transplant eligible newly diagnosed Multiple Myeloma (TE NDMM) patients final results
    Crusoe, Edvan
    Santos, Juliana
    Leal, JOanna
    Santos, Herbert
    Santos, Allan
    Almeida, Alessandro
    Santos, Mariane
    Lucas, Larissa
    Queiroz, Sarah
    Fonseca, Cleverson
    Adorno, Elisangela
    Vieira, Lucas
    Hungria, Vania
    Salvino, Marco
    Arruda, Maria da Gloria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S130 - S130
  • [16] CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (KCYD) IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS: INITIAL RESULTS OF A PHASE 1 STUDY
    Bringhen, S.
    Musto, P.
    Gay, F.
    Giuliani, N.
    Liberati, A. M.
    Pautasso, C.
    Ponticelli, E.
    De Paoli, L.
    Zambello, R.
    Ciccone, G.
    Carella, A. M.
    Boccadoro, M.
    Sonneveld, P.
    Palumbo, A.
    HAEMATOLOGICA, 2016, 101 : 520 - 520
  • [17] Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Initial Results from the Randomized Phase II HOVON-126/Nmsg 21.13 Trial
    Zweegman, Sonja
    van der Holt, Bronno
    Schjesvold, Fredrik H.
    Levin, Mark-David
    Stege, Claudia A. M.
    Waage, Anders
    Leijs, Maria Berhardina
    Klein, Saskia
    Szatkowski, Damian L.
    Broyl, A.
    Axelsson, Per
    Trung Hieu Do
    Knut-Bojanovska, Dorota
    van der Spek, Ellen
    Svirskaite, Asta
    Cunha, Sonia
    Hansson, Markus
    Sonneveld, Pieter
    Haukaas, Einar
    Abildgaard, Niels
    BLOOD, 2017, 130
  • [18] Bone remineralization of lytic lesions in newly diagnosed multiple myeloma (NDMM) patients treated with carfilzomib, lenalidomide, dexamethasone plus /- daratumumab induction regimen
    Meseha, Mina
    Abusamra, Murad
    Farooki, Azeez
    Derkach, Andriy
    Maclachlan, Kylee
    Hultcrantz, Malin
    Hassoun, Hani
    Shah, Urvi
    Lu, Sydney
    Mailankody, Sham
    Patel, Dhwani
    Lahoud, Oscar
    Shah, Gunjan
    Scordo, Michael
    Chung, David
    Landau, Heather
    Lesokhin, Alexander
    Korde, Neha
    Giralt, Sergio
    Usmani, Saad
    Tan, Carlyn
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S139 - S140
  • [19] Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma
    Baz, Rachid C.
    Shain, Kenneth H.
    Hussein, Mohamad A.
    Lee, Ji-Hyun
    Sullivan, Daniel M.
    Oliver, Elizabeth Finley
    Nardelli, Lisa A.
    Nodzon, Lisa A.
    Zhao, Xiuhua
    Ochoa-Bayona, Jose Leonel
    Nishihori, Taiga
    Dalton, William S.
    Alsina, Melissa
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (01) : 62 - 67
  • [20] Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Results from the Randomized Phase II HOVON-126/Nmsg 21#13 Trial
    Zweegman, Sonja
    Schjesvold, Fredrik H.
    van der Holt, Bronno
    Levin, Mark-David
    Stege, Claudia A. M.
    Waage, Anders
    Leijs, Maria B. L.
    Klein, Saskia K.
    Szatkowski, Damian L.
    Axelsson, Per
    Trung Hieu Do
    Knut-Bojanovska, Dorota
    van der Spek, Ellen
    Svirskaite, Asta
    Poddighe, Pino
    Stevens-Kroef, Marian
    Hansson, Markus
    van de Donk, Niels W. C. J.
    Haukas, Einar
    Sonneveld, Pieter
    Abildgaard, Niels
    BLOOD, 2018, 132
12345